ResearcherUniversitat de ValènciaActive in the last 2 years
Dimitri Dorcaratto
Matched on ORCID iD 0000-0001-9807-4689; OpenAlex author ID A5012945306. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 7
- 3D-PANC study protocol: Is three-dimensional imaging technology superior to computed tomography for assessing the response to neoadjuvant treatment in patients… Last author DOI 10.1016/j.cireng.2025.800256↗
- Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
- ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast pr… Co-author DOI 10.1016/j.trsl.2024.05.003↗
- Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice Co-author DOI 10.1038/s41598-021-85032-9↗
- Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. Co-author DOI 10.1038/s41598-020-74947-4↗
- Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Co-author DOI 10.1136/esmoopen-2020-000929↗
- Borderline resectable pancreatic cancer. Challenges and controversies. Co-author DOI 10.1016/j.ctrv.2018.06.006↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marina Garcés‐Albir · 4 shared papers, 2018–2026 · strength 0.68
- Paper 3D-PANC study protocol: Is three-dimensional imaging technology superior to computed tomography for assessing the respo… DOI 10.1016/j.cireng.2025.800256↗
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Luis Sabater-Orti · 3 shared papers, 2018–2024 · strength 0.32
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Paper Borderline resectable pancreatic cancer. Challenges and controversies. DOI 10.1016/j.ctrv.2018.06.006↗
- Marisol Huerta · 3 shared papers, 2018–2024 · strength 0.32
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Paper Borderline resectable pancreatic cancer. Challenges and controversies. DOI 10.1016/j.ctrv.2018.06.006↗
- Andrès M.R. Cervantes · 3 shared papers, 2018–2024 · strength 0.32
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Paper Borderline resectable pancreatic cancer. Challenges and controversies. DOI 10.1016/j.ctrv.2018.06.006↗
- Susana Roselló · 3 shared papers, 2018–2024 · strength 0.32
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Paper Borderline resectable pancreatic cancer. Challenges and controversies. DOI 10.1016/j.ctrv.2018.06.006↗
- Noelia Tarazona · 2 shared papers, 2020–2024 · strength 0.24
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Clara Alfaro‐Cervelló · 2 shared papers, 2020–2024 · strength 0.24
- Paper ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and iden… DOI 10.1016/j.trsl.2024.05.003↗
- Paper Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcom… DOI 10.1136/esmoopen-2020-000929↗
- Marta Cáceres · 2 shared papers, 2020–2021 · strength 0.21
- Paper Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic ad… DOI 10.1038/s41598-021-85032-9↗
- Paper Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. DOI 10.1038/s41598-020-74947-4↗
- Patricia Sánchez‐Velázquez · 2 shared papers, 2020–2021 · strength 0.21
- Paper Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic ad… DOI 10.1038/s41598-021-85032-9↗
- Paper Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. DOI 10.1038/s41598-020-74947-4↗
- Fernando Burdı́o · 2 shared papers, 2020–2021 · strength 0.21
- Paper Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic ad… DOI 10.1038/s41598-021-85032-9↗
- Paper Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. DOI 10.1038/s41598-020-74947-4↗
- Francisco X. Real · 2 shared papers, 2020–2021 · strength 0.21
- Paper Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic ad… DOI 10.1038/s41598-021-85032-9↗
- Paper Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. DOI 10.1038/s41598-020-74947-4↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.